Versamet Royalties Corp
VMET Nasdaq Mineral Royalty Traders Financials FY2024–FY2025
Last close · Oct 23, 2026
$8.23
1.1%What Versamet Royalties Corp does
No business description yet.
- Legal name
- Versamet Royalties Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 30, 2026
- Accession · CIK
- 0001104659-26-052847
0002080073
Revenue and margins
Versamet Royalties Corp had $34.8M of revenue in fiscal 2025, up 189.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Versamet Royalties Corp returned — to shareholders in fiscal 2025. The diluted share count rose 25.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Versamet Royalties Corp can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $1.4M | $3.7M |
| Interest coverage | 0.4x | 3.2x |
| Current ratio | 0.6x | 0.7x |
| Quick ratio | 0.6x | 0.7x |
| Total assets | $230M | $418M |
| Total liabilities | $18.9M | $184M |
| Shareholders' equity | $211M | $234M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✓ |
| Cash from operations is positive | ✓ | ✓ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 6 / 8 |
| Accruals ratio | −4.3% | 1.0% |
| Altman Z'' | 11.44 | 1.92 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $12.0M | $34.8M |
| Net interest income | $0.1M | $0.3M |
| Gross profit | $1.2M | $13.5M |
| Operating income | $1.4M | $38.8M |
| Interest expense | $3.6M | $12.2M |
| Pretax income | −$0.9M | $29.6M |
| Income tax | $1.6M | $9.3M |
| Net income | −$2.4M | $20.3M |
| Diluted EPS | −$0.03 | $0.21 |
| Diluted shares | 0.08B | 0.10B |
| Cash flow | ||
| Cash from operations | $7.4M | $16.9M |
| Stock-based compensation | $2.6M | $1.7M |
| Balance sheet | ||
| Cash and short-term investments | $1.4M | $3.7M |
| Current assets | $9.5M | $24.2M |
| Current liabilities | $16.9M | $32.9M |
| Total assets | $230M | $418M |
| Total liabilities | $18.9M | $184M |
| Shareholders' equity | $211M | $234M |
| Margins | ||
| Gross margin | 9.9% | 38.8% |
| Operating margin | 11.5% | 111.5% |
| Net margin | −20.4% | 58.5% |
| Net interest share of revenue | 1.2% | 0.8% |
| Returns | ||
| Return on capital employed | 0.6% | 10.1% |
| Return on equity | −1.2% | 9.1% |
| Return on assets | −1.1% | 6.3% |
| Return on tangible equity | −1.2% | 8.7% |
| Growth | ||
| Revenue growth | — | 189.1% |
| Share count change | — | 25.3% |
| Financial health | ||
| Interest coverage | 0.4x | 3.2x |
| Current ratio | 0.6x | 0.7x |
| Quick ratio | 0.6x | 0.7x |
| Capital allocation | ||
| Stock comp / revenue | 21.3% | 4.8% |
| Quality scores | ||
| Piotroski F-score | — | 6.0 |
| Altman Z'' | 11.4 | 1.9 |
| Accruals ratio | −4.3% | 1.0% |
Source: SEC EDGAR XBRL filings (CIK 0002080073). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.